

**Analysis of Systems of Care and Outcomes for Stage III
Melanoma Patients at Lehigh Valley Topper Cancer Institute
(2014-2019)**

Aidan Johnson

Suresh G. Nair MD

Follow this and additional works at: <https://scholarlyworks.lvhn.org/research-scholars>



Part of the [Medicine and Health Sciences Commons](#)

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Analysis of Systems of Care and Outcomes for Stage III Melanoma Patients at Lehigh Valley Topper Cancer Institute (2014-2019)

Aidan Johnson and Suresh G. Nair, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

Background

- Approximately **97,160** cases of melanoma are expected to be diagnosed by the end of 2023
 - Fifth** most common form of cancer.
 - Nearly **ten percent** will be classified as Stage III involving regional lymph node metastasis.
- Since 2015, three checkpoint inhibitor immunotherapy drugs have received FDA approval for adjuvant treatment after the excision of local melanoma.
 - ipilimumab, nivolumab, and pembrolizumab.
- Lehigh Valley Topper Cancer Institute (LVTCI), as the regional leader in melanoma care implemented melanoma multidisciplinary clinics (MDC), melanoma nurse navigation and participated in all three of the pivotal checkpoint inhibitor adjuvant trials.
- Over **90%** of recurrences for melanoma occur **within three years** of diagnosis
 - critical to swiftly eliminate the disease and maintain treatment to avoid relapse
 - the introduction of adjuvant immunotherapies is believed to do this.
- The objective of this study was to gather data to determine if the approval of adjuvant **immunotherapies led to more successful outcomes** with Stage III melanoma patients.

Methods

- Data Collection:
 - Reviewed the patient records for **122 patients** seen at LVCTI using both Mosaiq and Epic.
 - 66 patients during 2014-2016
 - 55 patients during 2017-2019
- Statistical Analysis:
 - Garnered percentages regarding several categories of care and compared the first period (2014-2016) to the second period (2017-2019) to determine the **effectiveness of the changes**.

Results

Stage III Melanoma Patient Data




Figure 1: Stage III Melanoma Patient Data

Outcomes

- FDA approval of adjuvant immunotherapy increased the use of the treatment regimens by **17%**.
- During this time period, there was a **21% increase** in the MDC visits and a near **30% increase** in nurse navigation.
- Overall, these combined factors led to:
 - 30%** increase in 3-year no evidence of disease
 - 15%** increase in 3-year survival
 - 28%** decrease in the recurrence rate
 - 30%** decrease in deaths due to melanoma

Conclusions

- As the region's leader in melanoma care, Lehigh Valley Topper Cancer Institute is always looking to improve patient outcomes and experience.
- LVTCI (**9%**) significantly exceeds the national average (**30%**) of stage III melanoma deaths.
 - Displaying the **impact on patient outcomes** from systems of care including sub-specialization, multi-disciplinary clinics, clinical trials and navigation
- Additionally, the FDA approval of ipilimumab, nivolumab, and pembrolizumab has **significantly reduced** recurrence rates.
 - Leading to a greater number of healthier, disease-free patients in the long-term
- Communicating this data with patients will **increase their confidence** in their treatment path and care at LVTCI.

All Data +
References!

